Indication

Differentiated thyroid carcinoma

Differentiated thyroid carcinoma is a malignant neoplasm originating from the follicular epithelial cells of the thyroid gland, representing the vast majority of all thyroid cancers. Read more about Differentiated thyroid carcinoma

9 drugs 9 manufacturers

Advertisement

Drugs that treat it

Common Differentiated thyroid carcinoma therapies.

Showing 1–9 of 9 drugs

Filter & compare in the drug finder →Opens the drug finder with Differentiated thyroid carcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Differentiated thyroid carcinoma.

Differentiated thyroid carcinoma is a malignant neoplasm originating from the follicular epithelial cells of the thyroid gland, representing the vast majority of all thyroid cancers.

It primarily encompasses papillary thyroid carcinoma and follicular thyroid carcinoma, characterized by malignant cells that largely retain histological and functional features of normal thyroid tissue, including thyroid-stimulating hormone responsiveness and the capacity for iodine uptake.

The condition predominantly affects adults, with a notable female predominance, and most commonly manifests as an asymptomatic, slow-growing neck mass or solitary thyroid nodule.

While differentiated thyroid carcinoma generally follows an indolent course with a favorable prognosis, advanced or refractory cases can exhibit local invasion into adjacent cervical structures, cervical lymph node metastasis, or hematogenous dissemination to distant sites such as the lungs and bones.

Personalize your experience

Follow Differentiated thyroid carcinoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it